Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Immunitor Announces Placebo-Controlled Trial of Its Therapeutic AIDS Vaccine

13.12.2004


Immunitor USA Inc., announces that its licensed vaccine candidate V-1 Immunitor (V1) has shown promising results in Phase II, placebo-controlled, clinical trial involving 47 HIV-infected individuals (http://www.emediawire.com/releases/2004/12/emw186195.htm)

The study was published in the special December issue of the Journal of Clinical Virology – the official journal of The Pan American Society for Clinical Virology and The European Society for Clinical Virology. The abstract of the paper is now available on PubMed - the website of the National Library of Medicine http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15567095

At the end of 6-month study volunteers who were treated with V1 had statistically significant increase in CD4-positive T-cell numbers (p=0.01). However, in the placebo group that has received sham pills, the changes in T-cell counts failed to reach the significance threshold (p=0.33). The clinical potential of V1 was further supported by an elevation in CD4/CD8 ratio among V1 recipients and decline in CD4/CD8 ratio in patients on placebo. The average weight gain among patients on V1 was 1.8 kg while placebo group lost 0.5 kg. These results indicate that V1 can delay or reverse the HIV disease progression without any concurrent toxicity.



"Our published data supports earlier published, Phase I studies of V1 demonstrating increase in T-lymphocyte numbers, decrease in viral load, body weight gain, and improved survival of end-stage AIDS patients,” said Vichai Jirathitikal, the inventor of the oral vaccine technology. "The study provides additional evidence that this type of vaccine might ultimately be effective as a safe and effective treatment for AIDS and potentially other autoimmune diseases as well."

" The very first clinical study of V1 was published in 2002. In just two years we were able to achieve the major milestone in drug development process, which is the pivotal Phase II trial. We have accomplished this despite major and obvious difficulties and we are looking forward to confirm such results in Phase III clinical trial," said Dr. Aldar S. Bourinbaiar, CEO.

Due to toxicity and drug resistance problems associated with conventional antiviral chemotherapy, the therapeutic use of AIDS vaccines is receiving increased attention in the medical community. There has been considerable experience with this type of approach, with several dozen clinical trials reported over the last twenty years. While the immune response appeared to change as a result of therapeutic vaccination in most, if not all studies, there was no demonstrable clinical benefit. Despite this setback many clinical studies of various therapeutic vaccines are in progress, which may eventually help to identify an effective strategy.

V-1 Immunitor is an experimental AIDS vaccine made as an ordinary pill and comprises heat- and chemically-inactivated viral antigens derived from the pooled blood of HIV-positive donors. V1, which is taken orally on a daily basis, is thought to function by modulating the mucosal immune response. This innovative method of vaccine administration places the emphasis on oral tolerization of alloantigens delivered through the gut. V1 is the first therapeutic AIDS vaccine that has shown the clinical improvement in AIDS patients when administered orally.

Dr. Aldar S. Bourinbaiar | Immunitor USA Inc

More articles from Health and Medicine:

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

nachricht Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Underwater acoustic localization of marine mammals and vehicles

23.11.2017 | Information Technology

Enhancing the quantum sensing capabilities of diamond

23.11.2017 | Physics and Astronomy

Meadows beat out shrubs when it comes to storing carbon

23.11.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>